(VIANEWS) – Shares of Pacific Biosciences of California (NASDAQ: PACB) rose by a staggering 25.3% in 10 sessions from $8.34 at 2022-11-09, to $10.45 at 15:54 EST on Wednesday, following the last session’s upward trend. NASDAQ is jumping 1.09% to $11,295.95, following the last session’s upward trend.

Pacific Biosciences of California’s last close was $10.62, 62.3% below its 52-week high of $28.17.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. develops, manufactures, and markets sequencing systems for complex genetic problems. PacBio’s Systems are used to monitor and analyze biochemical sequence reactions. The company also offers consumables such as single molecule real time (SMRT), cells and numerous reagent kit options. For example, the template preparation kit is designed to convert DNA into SMRTbell double stranded library formats. This includes molecular biology reagents such as ligase and buffers. The company also sells binding kits such as the modified DNA polymerase, which is used to bind SMRTbell library to the polymerase to prepare for sequencing. Sequencing kits include reagents that are required to perform on-instrument real-time sequencing including the phospholinked nuclear nucleotides. It serves commercial labs; research centers; genome centres; hospitals, public health laboratories, clinical research institutes, contract researchers organizations, academic institutions, pharmaceutical companies, and agricultural businesses. The company markets its products via a direct sales force throughout North America and Europe as well as distribution partners across Asia, Europe and the Middle East. Invitae Corporation has signed a partnership agreement for Pacific Biosciences of California, Inc.’s development and commercialization. The company used to be known as Nanofluidics, Inc. but changed its name in 2005 to Pacific Biosciences of California, Inc. Pacific Biosciences of California, Inc., was founded in 2000. It is located in Menlo Park, California.

Earnings per Share

Pacific Biosciences of California’s trailing 12 months EPS is $-0.34.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -43.76%.

More news about Pacific Biosciences of California (PACB).